目前正在寻找一种长效的口服形式的利沃多帕
Margaux Teil1,2, Jawad Al-Kassmy3, Mohammed Alsalmi4
1Montreal Neurological Institute-Hospital (The Neuro), Montreal, Canada.
Expert opinion on drug metabolism & toxicology
|July 14, 2025
概括
利沃多巴是帕金森病 (PD) 的关键治疗方法,但标准的口服形式会导致药物水平不稳定. 新的配方和输送方法旨在更好地控制PD患者的症状并减少PD患者的运动并发症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 利沃多巴是帕金森病 (PD) 的首要症状治疗方法.
- 目前的口服乐伏多巴配方表现出药理学挑战,包括血度波动,吸收延迟,以及由于代谢而导致的大脑分布不足.
- 这些局限性导致不理想的症状控制和运动并发症随着PD的进展.
研究的目的:
- 审查levodopa的药理动力学和药理动力学.
- 讨论当前口服乐伏多巴配方的局限性.
- 探索先进的口服配方和用于管理帕金森病的替代管理途径,特别是在先进阶段.
主要方法:
- 对levodopa的药理动力学和药理动力学数据的审查.
- 对口服乐伏多巴配方 (控制释放,延长释放) 最近进展的分析.
- 评估替代的注射途径,包括吸入的莱沃多巴和皮下的福斯莱沃多巴/福斯卡比多巴.
主要成果:
- 标准的口服乐伏多巴会导致帕金森病的不稳定血度和运动波动.
- 新的口服配方和替代的输送系统提供了更稳定的利沃多巴水平的潜力.
- 吸入的Levodopa和持续的皮下Foslevodopa/Foscarbidopa是有前途的,较少侵入性的选择,用于晚期PD.
结论:
- 管理帕金森病需要优化利沃多巴的输送,以克服传统口服配方的局限性.
- 先进的口服配方和替代途径,如吸入利沃多巴或皮下注射,对于提高治疗疗效至关重要.
- 考虑患者特定需求和潜在不良影响的个性化治疗方法对于高级帕金森病管理至关重要.
相关概念视频
01:24Parkinson's Disease: Treatment
385
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
385
01:30Prodrugs
3.0K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.0K
01:27Insulin Formulations: Types and Delivery
274
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
274
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
628
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
628
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.4K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.4K
01:15Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715